Biotech Values

[DewDiligence]

VIR IPOs 8.21*M shares @$20.00:

https://www.globenewswire.com/news-release/2019/10/10/1928390/0/en/Vir-Biotechnology-Announces-Pricing-of-Initial-Public-Offering.html

Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes.

Its current development pipeline consists of five product candidates targeting hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis.

*Assuming exercise of underwriter’s option.